Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 5/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201552 | 0.83 | HPGDS (0.52) | PDE2AUSP30 | |
| SCHEMBL27201684 | 0.79 | HDAC4 (0.47) | HDAC4F10GFERCCR5KCNH2 | |
| SCHEMBL27201476 | 0.78 | HDAC4 (0.46) | HDAC4PDE2AF10USP30CCR5 | |
| SCHEMBL25521500 | 0.78 | IRAK4 (0.45) | HDAC4F10USP30CCR5KCNH2 | |
| SCHEMBL3312540 | 0.72 | ALDH1A1 (0.62) | HSD11B1 | |
| SCHEMBL27201495 | 0.71 | IRAK4 (0.54) | HDAC4IRAK4 | |
| SCHEMBL30834117 | 0.71 | IRAK4 (0.47) | F10USP30IRAK4 | |
| SCHEMBL6347014 | 0.70 | HSD11B1 (0.53) | PDE2AUSP30PDE3AHSD11B1 | |
| SCHEMBL27201599 | 0.70 | JAK2 (0.43) | PDE2APDE3AHSD11B1 | |
| SCHEMBL5762778 | 0.70 | IRAK4 (0.50) | HDAC4F10USP30KCNH2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HDAC4 2313/4885PDE2A 4487/4885F10 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.